Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Transfusion

• Publication date

  2013-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1537-2995.2012.03959.xPMID 23176347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center

  2012cited by this paper
• A multi‐centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion

  2011cited by this paper
• Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.

  2011cited by this paper
• Dose of prophylactic platelet transfusions and prevention of hemorrhage.

  2010cited by this paper
• Intercept for Pathogen Inactivation (pi) in Platelet Concentrates (pc) Effectively Prevents Transfusion-associated Graft-versus-host Disease (ta-gvhd)

  2010cited by this paper
• Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

  2010cited by this paper
• Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

  2009influential reference
• An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment

  2008influential reference
• A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

  2008cited by this paper
• Patient and product factors affecting platelet transfusion results

  2008cited by this paper
• A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma.

  2006cited by this paper
• Prospective, paired crossover comparison of multiple, single‐needle plateletpheresis procedures with the Amicus and Trima Accel cell separators

  2006cited by this paper
• Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

  2005cited by this paper
• Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

  2005influential reference
• Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

  2005cited by this paper
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

  2004cited by this paper
• Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.

  2003cited by this paper
• Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

  2003cited by this paper
• Guidelines for the use of platelet transfusions

  2003cited by this paper
• A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets

  2002influential reference
• Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study

  2000cited by this paper
• Inactivation of Viruses, Bacteria, Protozoa and Leukocytes in Platelet and Red Cell Concentrates

  2000cited by this paper
• Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution

  1999influential reference
• Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation—a prospective analysis

  1998cited by this paper
• A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions

  1993cited by this paper
• Results

  1969cited by this paper

• Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage

  2022cites this paper
• Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination

  2022cites this paper
• Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial

  2021cites this paper
• Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission

  2020cites this paper
• The effect of gamma irradiation on platelet redox state during storage

  2020cites this paper
• Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects

  2020cites this paper
• The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

  2019cites this paper
• Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.

  2019cites this paper
• Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days

  2019cites this paper
• Culture-Derived Human Platelets for Clinical Transfusion

  2019cites this paper
• Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals

  2018cites this paper
• Prevention of transfusion‐associated graft‐versus‐host disease with pathogen‐reduced platelets with amotosalen and ultraviolet A light: a review

  2017cites this paper
• Pathogen-reduced platelets for the prevention of bleeding.

  2017cites this paper
• Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance

  2017cites this paper
• Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.

  2016cites this paper
• Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela

  2016cites this paper
• Metabolomic profiling highlights oxidative damages in platelet concentrates treated for pathogen inactivation and shows protective role of urate

  2016cites this paper
• In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

  2015cites this paper
• In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB‐treated platelet concentrates

  2015cites this paper
• Hemostatic Function and Transfusion Efficacy of Apheresis Platelet Concentrates Treated with Gamma Irradiation in Use for Thrombocytopenic Patients

  2014cites this paper
• Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus.

  2014cites this paper
• The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.

  2014cites this paper
• LC-MS/MS Analysis and Comparison of Oxidative Damages on Peptides Induced by Pathogen Reduction Technologies for Platelets

  2014cites this paper
• Update on the use of pathogen‐reduced human plasma and platelet concentrates

  2013cites this paper
• Platelet transfusion: basic aspects.

  2013cites this paper
• Einführung der Pathogeninaktivierung für Thrombozytenkonzentrate in der Schweiz

  2013cites this paper